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Abstract
Background: Intraoperative Radiotherapy (IORT) is a method by which a critical radiation dose
is delivered to the tumour bed immediately after surgical excision. It is being investigated whether
a single high dose of radiation will impart the same clinical benefit as a standard course of external
beam therapy. Our centre has four Photon Radiosurgery Systems (PRS) currently used to irradiate
breast and neurological sites.
Materials and methods: The PRS comprises an x-ray generator, control console, quality
assurance tools and a mobile gantry. We investigated the dosimetric characteristics of each source
and its performance stability over a period of time. We investigated half value layer, output
diminution factor, internal radiation monitor (IRM) reproducibility and depth-doses in water. The
half value layer was determined in air by the broad beam method, using high purity aluminium
attenuators. To quantify beam hardening at clinical depths, solid water attenuators of 5 and 10 mm
were placed between the x-ray probe and attenuators. The ion chamber current was monitored
over 30 minutes to deduce an output diminution factor. IRM reproducibility was investigated under
various exposures. Depth-dose curves in water were obtained at distances up to 35 mm from the
probe.
Results: The mean energies for the beam attenuated by 5 and 10 mm of solid water were derived
from ICRU Report 17 and found to be 18 and 24 keV. The average output level over a period of
30 minutes was found to be 99.12%. The average difference between the preset IRM limit and the
total IRM count was less than 0.5%. For three x-ray sources, the average difference between the
calculated and actual treatment times was found to be 0.62% (n = 30). The beam attenuation in
water varied by approximately 1/r3.
Conclusion: The x-ray sources are stable over time. Most measurements were found to lie within
the manufacturer's tolerances and an intercomparison of these checks suggests that the four x-ray
sources have similar performance characteristics.
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Background
The past 20 years have seen a distinct shift in the paradigm
used in the treatment of breast cancer, away from radical
interventions toward more conservative techniques. Ran-
domised clinical trials have shown that breast conserving
surgery allied to external beam radiotherapy compares
favourably with more radical procedures such as mastec-
tomy [1-9]. However, the external beam radiation fields
still encompass all of the breast tissue – healthy and can-
cerous. Intraoperative radiotherapy, using an innovative
miniature x-ray source avoids unnecessary treatment to
the whole breast and delivers a critical dose to the tumour
bed only. It has also been shown to be effective in the
treatment of intracranial malignancies [10-12]. Ninewells
Hospital currently uses the Photon Radiosurgery System
(PRS – Carl Zeiss Surgical GmbH, Oberkochen, Germany)
to treat breast and neurological tumours. The operation of
four PRS x-ray sources was compared over a period of six
months. The parameters measured were output trends,
half value layer (HVL), output diminution factor, internal
radiation monitor (IRM) values and depth doses in water.
Methods
Device description
The Photon Radiosurgery System includes an x-ray gener-
ator capable of delivering a prescribed therapeutic radia-
tion dose directly to the tumour bed during the surgical
procedure. The device itself weighs 1.62 kg, has dimen-
sions 17.5 × 11 × 7 cm with a 3.2 mm diameter and 100
mm length chromium nitride coated probe. The X-ray
source (XRS) is powered by a portable, electronic control
console. The PRS is supplied with a set of components,
which facilitate accurate alignment of the XRS probe as
well as quality assurance checks [13].
A s  s h o w n  i n  f i g u r e  1 ,  a n  e l e c t r o n  b e a m  i s  a c c e l e r a t e d
through a high-voltage field (range 30–50 kV in 10 kV
increments) and then passes through a deflection cham-
ber to control beam position and to ensure the beam
passes down the centre of the probe. The beam current is
selectable (5, 10, 20 and 40 μA). After travelling down the
evacuated, magnetically shielded probe, the electron
beam strikes a thin gold target (1 μm) at the probe tip pro-
ducing x-ray photons whose mean effective energies are
typically in the 5–25 keV range. The distal 20 mm of the
probe is fabricated from beryllium (0.5 μm), which is
transparent to very low energy x-ray photons [14].
The x-rays are emitted from the tip in a spherical symmet-
rical pattern resulting in a dose rate in tissue of approxi-
mately 120 Gy per hour at 10 mm from the probe tip [14].
Other research has shown that the relative biological
effectiveness at clinically relevant doses and dose rates for
this very low-energy x-ray source is considerably greater
than unity [15-18].
Output trends
Weekly output constancy checks, based on the manufac-
turer's recommendations, were carried out on four x-ray
sources over an extended period. Very low kV x-rays pro-
duced at the tip of the probe are detected by an internal
radiation monitor (IRM). The IRM uses a radiation detec-
tor that is internal to the XRS and it detects radiation,
which passes back along the path of the electron beam. An
external radiation monitor (ERM) provides an independ-
ent check on the correct performance of the XRS during
radiation delivery. It serves as a complementary method
of monitoring dose delivery in that it detects scattered
radiation exiting the patient. Radiation detected by the
ERM is converted to an output pulse rate related to the
radiation intensity. At the start of treatment, the output
pulse rate from the ERM is measured and provides a base-
line value against which successive measurements are
compared. The manufacturer's recommended IRM/ERM
test procedure was used to check the response of both the
internal and external radiation monitors. The ERM was
connected to the ERM Test Adapter and docked with the
XRS Probe under test.
The test first measures the background counts detected via
the IRM and ERM radiation monitors over a 30 second
period. The complete test takes approximately 8 minutes
and cycles through all the kV and μA combinations
including 50 kV and 40 μA. The IRM count rate obtained
during this verification procedure is used in treatment
administration. The IRM count rate in Hz is multiplied by
the treatment time in seconds to give the absolute number
of IRM counts at which the treatment is terminated. The
output of three x-ray sources was monitored in terms of
the internal count rate over a period of 25 weeks. The first
value obtained at commissioning was used as the baseline
for each x-ray source and subsequent readings were com-
pared to this value.
Half Value Layer
The HVLs for all the x-ray sources was determined in air by
a broad beam method, in which the x-ray probe is placed
20 cm away from the ionisation chamber, with high
purity aluminium attenuators placed near the midpoint.
The attenuators ranged in thickness from 0.03 to 1.22
mm. We investigated a single x-ray probe to ascertain the
effects of beam hardening at clinical depths relevant to
our treatment of invasive intracranial malignancies and
early stage breast cancer. Solid water WT1 (GAMMEX
RMI, Wisconsin, USA) attenuators 5 mm and 10 mm
thick were placed between the x-ray probe and the alu-
minium attenuators, approximately 2 cm away from the
probe. The equivalent energies for the unattenuated beam
and for the beam attenuated by 5 mm and 10 mm of solid
water were derived from tabulated data in ICRU Report 17
[19]Radiation Oncology 2007, 2:11 http://www.ro-journal.com/content/2/1/11
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Output diminution factor
To determine the constancy of output from the x-ray
sources, the ion chamber current was monitored over a
period of 30 minutes equivalent to typical clinical treat-
ment duration. After the full verification procedure, a par-
allel plate ion chamber (Type N23342, PTW, Freiburg,
Germany) calibrated in terms of exposure was coupled to
the PAICH (Probe Adjuster Ion Chamber Holder) and the
x-ray source to be tested. The dosemeter (Unidos 10005–
50234) was switched on and left for 30 minutes to attain
thermal and electronic equilibrium. The settings used
were 50 kV and 40 μA to mimic clinical use and the run
time set to 32.25 minutes. The uncorrected current read-
ings in pA were taken at 2-minute intervals up to 32 min-
utes giving 16 readings in all.
IRM reproducibility and linearity
Reproducibility of the IRM dosimetry system was investi-
gated for the four X-ray sources under various exposures
[20]. Exposure was controlled using a pre-set number of
IRM counts at a count rate equal to that obtained during
the verification of each of the x-ray sources. A beam volt-
age of 50 kV and a beam current of 40 μA were used. Meas-
urements were made for exposures equivalent to 1, 5, 10
and 15 minutes.
The linearity of the IRM dosimetry system was ascertained
at the clinical treatment voltage for the range of beam cur-
rent options offered by the PRS system. A 50 kV accelerat-
ing potential was selected, the number of counts set to 5 ×
106 and beam current chosen as 10, 20 and then 40 μA.
For each combination of voltage and current, a full verifi-
cation of the x-ray source must be performed.
Reproducibility with probe orientation
A succession of exposures was made with beam parame-
ters of 50 kV and 40 μA. The probe was rotated through
0°, 45°, 90°, 135° and 180° to the vertical plane. Three
exposures, each of 2 minutes duration were made with a
soft x-ray ionisation chamber placed 20 mm from the
probe tip. The mean of three readings in coulombs was
calculated at each probe orientation.
Constancy of treatment delivery time
After a full verification procedure the IRM limit corre-
sponding to 2 minutes was calculated based on the meas-
ured IRM rate in hertz. A beam voltage of 50 kV and a
beam current of 40 μA were selected and 30 sequential
exposures each of 2 minutes duration were made. The
actual treatment time, that is the beam-on time was
recorded and compared to the preset treatment time.
We have used three x-ray sources clinically for a total of 52
treatments. A hardcopy of the treatment delivery is pro-
duced by the PRS controller and includes the actual beam-
on time. We compared these with the calculated values
entered on the treatment calculation sheets to determine
the time divergence under clinical conditions.
X-Ray Source (XRS) Figure 1
X-Ray Source (XRS). Cross sectional representation of the miniature x-ray source showing the x-ray tube, electron gun, 
beam deflector and probe. The radiation dose distribution is spherical due to dithering of the electron beam onto the gold tar-
get.Radiation Oncology 2007, 2:11 http://www.ro-journal.com/content/2/1/11
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Depth dose in water
Depth-dose curves were obtained by measuring the cham-
ber output at distances of between 12 and 35 mm away
from the probe tip in a water phantom of dimensions 300
× 300 × 200 mm. The ionisation chamber was placed as
close as possible to the outer surface of the water phantom
to minimise the effect of air gaps. The position of the x-ray
source was then adjusted such that the tip of the probe
was just in contact with the inner wall of the phantom and
care was taken not to accidentally bend the probe in doing
so. The minimum distance away from the probe tip at
which the ionisation chamber could be positioned was 12
mm, accounted for by the perspex wall thickness (10 mm)
of the custom-built water phantom and the recessed
depth (2 mm) of the chamber window as shown in figure
2.
We acquired depth dose data in water to reduce the uncer-
tainties involved in converting from an air measurement
to a measurement in water. In addition, a comparison was
made between measured depth doses and corresponding
values obtained from an analytic fit of each of the depth
dose curves [14].
Results
Output trends
Full system verification was performed on each of three x-
ray sources on a weekly basis for 25 weeks and the value
of the internal rate monitor after 3 minutes (50 kV, 40 μA)
was recorded. Figure 3 shows a plot of the internal count
rate against time showed an average variation from the
baseline values of 0.67% (range 0.24% – 1.22%).
Half value layer
The mean HVL for the four sources was found to be 0.11
mmAl (range 0.10 – 0.12 mmAl) as shown in figure 4.
Based on a density of Aluminium of 2.699 × 103 kg.m-3
and using interpolated mass attenuation coefficients (μ/
ρ) from ICRU Report 17, the mean equivalent energy for
the four sources was 10.75 keV (range 10.5 – 11.0 keV).
This is comparable to the equivalent energy found for a
single x-ray source by Beatty et al [14].
Measurements made at 5 mm deep in solid water resulted
in a first HVL of 0.54 mm Al and an equivalent photon
energy of 18.0 keV. At 10 mm deep, beam hardening
increased the first HVL to 1.11 mm Al with an equivalent
photon energy of 23.5 keV.
Output diminution factor
A plot of output versus elapsed time shows definite, repro-
ducible output reduction as seen in figure 5. A difference
between the initial and final current readings was consist-
ently observed and the mean reduction was 1.58%, (range
0.54% – 2.22%). The average output level for all sources
over a period of 30 minutes was found to be 99.12%,
(range 97.78% – 100%). This reduction in output is small
but for the purposes of dose accuracy, should be included
in the dose calculation [14].
IRM reproducibility and linearity
A measure of the internal radiation monitor reproducibil-
ity was obtained from the difference between the actual
beam-on time and the preset times of 1, 5, 10 and 15 min-
utes for each x-ray source. The mean difference for the four
sources was found to be 0.23% (range 0.13% – 0.35%).
For all four sources, a plot of IRM rate versus beam current
was found to be linear.
Reproducibility with probe orientation
For all four x-ray sources, the average difference between
the mean reading at each orientation and the overall
mean was found to be 0.49% (range 0.42% – 0.64%).
This difference is greater than that found in a previous
study where a single x-ray source was investigated [14].
The difference can be accounted for by the fact that our
measurements were performed at five angles rather than
three and we intercompared four x-ray sources.
Constancy of treatment delivery time
Based on 30 sequential exposures of 2 minutes each, the
average difference or all four x-ray sources between the
preset and actual treatment times was found to be 0.55%
(range 0.41% – 0.66%).
Analysis of the calculated and actual clinical treatment
times showed a slightly higher average difference of
0.62% (range 0.53 – 0.74%) over a mean treatment time
of 26.27 minutes. This difference arises because x-ray pro-
duction does not stop instantaneously when the x-ray
source is turned off. This in turn is due to short delays, typ-
ically less than 1 millisecond, in the electronics that turn
the x-rays off. In our clinical experience, the maximum
difference between the actual treatment time and the cal-
culated treatment time was 2.65%.
Depth dose in water
Figure 6 shows a comparison of the depth dose curves
obtained in water at 50 kV and 40 μA for all four x-ray
sources. The dose rate was normalised to 100% at 10 mm
deep to mimic the prescription depth we use for breast
treatments. It was found that beam attenuation varies by
approximately 1/r3 as previously reported [14].
Figure 7 shows that the percentage difference between the
measured depth doses and an analytical (power) fit to the
data varied in the range ± 2%, again comparable to the
findings by Beatty et al [14].Radiation Oncology 2007, 2:11 http://www.ro-journal.com/content/2/1/11
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Set-up used for Depth Dose Measurements Figure 2
Set-up used for Depth Dose Measurements. Experimental set-up used to obtain Depth-Dose curves showing the x-ray 
source, custom-built water phantom and acrylic backscatter material of dimensions 30 cm × 30 cm × 10 cm. A low kV x-ray 
parallel plate ionisation chamber (PTW N23342) was used to measure the dose at distances of 10 to 35 mm away from the tip 
of the probe, in increments of 1 mm.Radiation Oncology 2007, 2:11 http://www.ro-journal.com/content/2/1/11
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Output trend with time Figure 3
Output trend with time. The output of three x-ray sources was monitored over a period of 25 weeks and compared to the 
baselines values. Although the absolute output of each source is different, the variation from the baseline was less than 1% in 
each case.
Comparison of normalised Half Value Layers (HVL) Figure 4
Comparison of normalised Half Value Layers (HVL). The HVLs for all the x-ray sources was determined by a broad 
beam method, in which the x-ray probe is placed 20 cm away from the ionisation chamber, with high purity aluminium attenu-
ators placed near the midpoint. The HVL for each x-ray source was approximately 0.1 mm Al.Radiation Oncology 2007, 2:11 http://www.ro-journal.com/content/2/1/11
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Output Diminution Factor Figure 5
Output Diminution Factor. To determine the constancy of output from the x-ray sources, the ion chamber current was 
monitored over a period of 30 minutes equivalent to typical clinical treatment duration. A difference between the initial and 
final current readings was consistently observed and the mean reduction was 1.58%.
Depth Dose Comparison Figure 6
Depth Dose Comparison. Depth-dose curves were obtained by measuring the chamber output at distances of between 12 
and 35 mm away from the probe tip in water. The ionisation chamber was placed as close as possible to the outer surface of 
the water phantom to minimise the effect of air gaps. It was found that beam attenuation varies by approximately 1/r3as previ-
ously reported [14, 20].Radiation Oncology 2007, 2:11 http://www.ro-journal.com/content/2/1/11
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Discussion
This paper describes how we performed a functional inter-
comparison of four PRS very low kilovoltage intraopera-
tive radiotherapy units used for the treatment of early
stage breast cancer and intracranial metastases. Our centre
was in a unique position to perform this study due to the
fact that we have four of the miniature x-ray sources avail-
able. In comparison, most other centres participating in
the Targit clinical trial have one or two units.
We are currently treating patients with early stage breast
cancer and those with invasive intracranial malignancies.
However, we also envisage treating patients with colorec-
tal cancer and cancers of the upper gastrointestinal tract. It
is therefore likely that we will need to use different x-ray
sources for different treatment sites. This highlights the
need to perform a functional intercomparison amongst
our four x-ray sources to ensure that the prescribed dose in
each case was being delivered, regardless of which x-ray
source was used.
We perform a weekly verification procedure based on the
manufacturer's recommendations on each x-ray source,
and data form this has enabled us to observe the output
trends of our sources. Over a six-month period, we
observed a deviation from baseline values of less than ±
1% for all sources. This compares favourably with the out-
put constancy of ± 2% recommended in 1997 by the Euro-
pean Commission [21].
In general, due to the rapid dose fall-off from the PRS x-
ray sources, absolute dosimetric measurements are diffi-
cult to reproduce as the dose in water can vary considera-
bly across the volume of a detector. Further, the low-
energy x-ray spectrum hardens rapidly with distance in
water and this can affect dosimetric parameters such as
energy absorption coefficients and tissue equivalence of
phantom materials [22].
In terms of the uncertainty of the depth dose measure-
ments, we quantified it as follows. Temperature and pres-
sure correction factor (± 0.3%), calibration factor of the
ion chamber (± 2.2%), calibration factor of the electrom-
eter (± 0.5%), ion chamber current (± 3.4%), output
decay factor (± 1.6%), absolute calibration in water (±
9%) and relative dose calibration in water (± 4%). Com-
bining these errors in quadrature results in an overall error
of ± 10.8%. This corresponds to a positional uncertainty
in the prescribed dose of ± 0.22 mm at a depth of 5 mm
increasing to ± 0.44 mm at a depth of 10 mm in water.
Difference between measured data and analytic fit Figure 7
Difference between measured data and analytic fit. This figure shows that the percentage difference between the meas-
ured depth doses and an analytical (power) fit to the data varied approximately in the range ± 2%, again comparable to the find-
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This shows that the most significant error in determining
the output dose lies in the measurement of the position of
the chamber relative to the x-ray source.
Conclusion
We have performed an intercomparison of four minia-
ture, low kV x-ray sources currently used in an interna-
tional clinical trial for the treatment of early stage breast
cancer. The characteristics intercompared were output sta-
bility, half value layer, output diminution factor, internal
radiation monitor reproducibility and variation of depth
doses in water. The x-ray sources have proven to be stable
over time. Most measurements were found to lie within
the manufacturer's tolerances and an intercomparison of
these checks show that the four x-ray sources have similar
performance characteristics.
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